As part of a continued effort to focus on its Diagnostics Information Services business, Quest Diagnostics Inc. has sold its colorectal cancer (CRC) screening test business Enterix Inc. to Australian oncology testing firm Clinical Genomics Technologies Pty. Ltd. (Sep.)
The history among the three firms goes back to 2003, when Quest got US rights to sell Enterix’s in-home fecal occult immunochemical colorectal cancer test InSure. Three years later, Quest...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?